Aclaris Therapeutics (ACRS) Interest Coverage Ratio (2014 - 2026)
Aclaris Therapeutics' (ACRS) quarterly Interest Coverage Ratio came in at 1.51 in Q1 2026, up 93.8% year-on-year from 0.78 in Q1 2025, and up 42.84% quarter-over-quarter from 2.64 in Q4 2025.
Aclaris Therapeutics (ACRS) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Interest Coverage Ratio history runs 13 years deep, the most recent figure standing at 1.51 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 93.8% year-over-year to 1.51 in Q1 2026; TTM through Mar 2026 was 5.48, a 97.12% increase from a year earlier, with the FY2025 full-year figure at 0.39, up 38.75% from the prior year.
- Interest Coverage Ratio grew to 1.51 in Q1 2026 per ACRS's latest filing, from 2.64 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.16 in Q4 2022 and bottomed at 289.07 in Q4 2023.
- The 5-year median for Interest Coverage Ratio is 7.95 (2025), against an average of 36.17.
- Across the five-year window, Interest Coverage Ratio tumbled 183496.49% in 2023 and jumped 93.85% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.16 in 2022, then tumbled by 183496.49% to 289.07 in 2023, then jumped by 88.38% to 33.58 in 2024, then surged by 92.13% to 2.64 in 2025, then jumped by 42.84% to 1.51 in 2026.
- Per Business Quant, the three latest ACRS Interest Coverage Ratio figures stand at 1.51 (Q1 2026), 2.64 (Q4 2025), and 7.95 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | -1.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.51 |
| Dec 31, 2025 | -2.64 |
| Sep 30, 2025 | -7.95 |
| Jun 30, 2025 | -36.38 |
| Mar 31, 2025 | -24.37 |
| Dec 31, 2024 | -33.58 |
| Sep 30, 2024 | -129.27 |
| Jun 30, 2024 | -26.84 |
| Mar 31, 2024 | -38.87 |
| Dec 31, 2023 | -289.07 |
| Sep 30, 2023 | -8.58 |
| Jun 30, 2023 | -4.95 |
| Mar 31, 2023 | -6.31 |
| Dec 31, 2022 | -0.16 |
| Sep 30, 2022 | -1.36 |
| Jun 30, 2022 | -1.94 |
| Mar 31, 2022 | -1.03 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | -1.12 |
| Jun 30, 2021 | -1.03 |